Becton Dickinson (BRSE:000912061) - Aktienkurs, Nachrichten und Analyse

000912061 Aktienübersicht

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. Mehr Details

000912061 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	3/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	3/6
Dividenden	4/6

Belohnungen

44.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 15.74% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 27.9%

Risikoanalyse

Aktien sind hochgradig illiquide

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Becton, Dickinson and Company Wettbewerber

Sonova Holding

SWX:SOON

CHF 19.0b

Straumann Holding

SWX:STMN

CHF 18.1b

Medacta Group

SWX:MOVE

CHF 2.3b

Alcon

SWX:ALC

CHF 37.8b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Becton Dickinson
Historische Aktienkurse
Aktueller Aktienkurs	US$238.02
52-Wochen-Hoch	US$253.43
52-Wochen-Tief	US$238.02
Beta	0.59
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	-2.22%
33 Jahre Veränderung	-2.21%
5 Jahre Veränderung	26.81%
Veränderung seit IPO	94.30%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	000912061	CH Medical Equipment	CH Markt
7D	0%	-3.3%	-1.1%
1Y	-2.2%	16.9%	8.2%

Rendite im Vergleich zur Industrie: 000912061 unter dem Niveau der Branche Swiss Medical Equipment , die im vergangenen Jahr eine Rendite von 15.6% erzielte.

Rendite vs. Markt: 000912061 hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 7 erzielte.

Preisvolatilität

Is 000912061's price volatile compared to industry and market?
000912061 volatility
000912061 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	6.9%
10% least volatile stocks in CH Market	1.6%

Stabiler Aktienkurs: 000912061 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von 000912061 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1897	75,000	Tom Polen	www.bd.com

Becton, Dickinson and Company's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Becton Dickinson im Vergleich zum Marktanteil des Unternehmens?
000912061 grundlegende Statistiken
Marktanteil	CHF 65.43b
Gewinn(TTM)	CHF 1.86b
Umsatz(TTM)	CHF 19.69b

35.1x

Kurs-Gewinn-Verhältnis

3.3x

Kurs-Umsatz-Verhältnis

Ist 000912061 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
000912061 Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$20.08b
Kosten der Einnahmen	US$10.59b
Bruttogewinn	US$9.49b
Sonstige Ausgaben	US$7.59b
Umsatz	US$1.90b

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	6.66
Bruttomarge	47.25%
Nettogewinnspanne	9.46%
Schulden/Eigenkapital-Verhältnis	64.2%

Wie hat sich 000912061 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.5%

Aktuelle Dividendenrendite

52%

Ausschüttungsquote

000912061 Aktienübersicht

Belohnungen

Risikoanalyse

Becton, Dickinson and Company Wettbewerber

SWX:SOON

CHF 19.0b

SWX:STMN

CHF 18.1b

SWX:MOVE

CHF 2.3b

SWX:ALC

CHF 37.8b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Recent updates

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Erträge & Einnahmen